公开(公告)号：US11952375B2

公开(公告)日：2024-04-09

申请号：US17484564

申请日：2021-09-24

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst ,  Bennett C. Borer ,  Samuel Sperry ,  Jo Ann Z. Wilson

IPC: C07D471/04 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D471/04 ,  C07B2200/13

Abstract: The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione:




The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US11878015B2

公开(公告)日：2024-01-23

申请号：US17396187

申请日：2021-08-06

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Justin T Ernst ,  Paul A. Sprengeler ,  Siegfried H. Reich ,  Samuel Sperry

IPC: A61K31/506 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02

CPC classification number: A61K31/506 ,  A61P29/00 ,  A61P35/02

Abstract: The present invention relates to compounds according to Formula (I):




or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X1, X2, R1, R2, R3 and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

公开(公告)号：US20190275039A1

公开(公告)日：2019-09-12

申请号：US16233507

申请日：2018-12-27

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Justin T. Ernst ,  Paul A. Sprengeler ,  Siegfried H. Reich ,  Samuel Sperry

IPC: A61K31/506 ,  A61P29/00 ,  A61P35/02

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X1, X2, R1, R2, R3 and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

公开(公告)号：US20220119387A1

公开(公告)日：2022-04-21

申请号：US17484564

申请日：2021-09-24

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Siegfried H. REICH ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst ,  Bennett C. Borer ,  Samuel Sperry ,  Jo Ann Z. Wilson

IPC: C07D471/04

Abstract: The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US11286268B1

公开(公告)日：2022-03-29

申请号：US16916820

申请日：2020-06-30

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： Samuel Sperry ,  Alan X. Xiang ,  Justin T. Ernst ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Mike Shaghafi ,  Theo Michels ,  Christian Nilewski ,  Chinh Viet Tran ,  Garrick Kenneth Packard ,  Alan Grubbs ,  Kaveri Urkalan ,  Takasuke Mukaiyama

IPC: C07D519/00 ,  C07D495/04

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US11130757B2

公开(公告)日：2021-09-28

申请号：US16661507

申请日：2019-10-23

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst ,  Bennett C. Borer ,  Samuel Sperry ,  Jo Ann Z. Wilson

IPC: A61K31/506 ,  A61P35/00 ,  C07D471/04

Abstract: The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20220096472A1

公开(公告)日：2022-03-31

申请号：US17396187

申请日：2021-08-06

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Justin T. Ernst ,  Paul A. Sprengeler ,  Siegfried H. Reich ,  Samuel Sperry

IPC: A61K31/506 ,  A61P29/00 ,  A61P35/02

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X1, X2, R1, R2, R3 and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

公开(公告)号：US11083727B2

公开(公告)日：2021-08-10

申请号：US16233507

申请日：2018-12-27

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Justin T. Ernst ,  Paul A. Sprengeler ,  Siegfried H. Reich ,  Samuel Sperry

IPC: C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D487/04 ,  C07D491/20 ,  C07D495/20 ,  A61K31/506 ,  A61P29/00 ,  A61P35/02

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X1, X2, R1, R2, R3 and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.